

## CYP2C9: phenytoin

1676 to 1682

\*1 = no CYP2C9 gene variant, normal activity, \*2 = CYP2C9 gene variant with decreased activity, \*3 = CYP2C9 gene variant with strongly decreased activity, CI = confidence interval, C/D-ratio = concentration/dose ratio = dose-corrected plasma concentration,  $Cl_{or}$  = oral clearance,  $C_{ss}$  = steady-state plasma concentration, DRESS = drug reaction with eosinophilia and systemic symptoms, HR = hazard ratio, HSS = hypersensitivity syndrome, IM = intermediate metaboliser, other genotype (decreased CYP2C9 enzyme activity due to the presence of one gene variant with decreased activity other than \*2 or \*3), MPE = maculopapular eruption, NM = normal metaboliser (\*1/\*1) (normal enzyme activity), NS = non-significant,  $OR_{(corr)}$  = (corrected) odds ratio, p-HPPH = 5-(para-hydroxy-phenyl)-5-phenylhydantoin, PM = PM, other genotypes = combination of reduced-activity alleles including at least one allele other than \*2 or \*3, PM = PM other = poor metaboliser, other genotype (strongly decreased CYP2C9 enzyme activity due to the presence of two gene variants with decreased activity, of which at least one other than \*2 or \*3), S = significant, SJS = Stevens-Johnson syndrome, SmPC = Summary of Product Characteristics, TDM = therapeutic drug monitoring, TEN = toxic epidermal necrolysis,  $V_{max}$  = maximum elimination rate

**Disclaimer:** The KNMP Pharmacogenetics Working Group formulates optimal drug recommendations on the basis of the available evidence. If these optimal recommendations cannot be followed due to practical limitations, e.g. because therapeutic drug monitoring or lower doses are not available, healthcare professionals should consider the best available alternative.

### Brief summary and justification of choices:

Phenytoin is predominantly metabolised by CYP2C9 (90%) and to a lesser extent by CYP2C19 (10%). Phenytoin exhibits non-linear pharmacokinetics. With chronic use, phenytoin induces CYP450 enzymes, primarily CYP2C9 and CYP2C19. So, phenytoin induces its own metabolism. However, because CYP2C9 and CYP2C19 are saturable at high phenytoin serum concentrations, small incremental doses may produce very substantial increases in serum concentrations, when these are in the upper range.

Polymorphisms in the CYP2C9 gene lead to an enzyme with reduced activity. This may increase plasma concentration at a certain dose, and may also lead to an increase in the incidence of side effects.

\*1/\*3, \*2/\*2, \*2/\*3: Human studies found an increased incidence of side effects for these genotypes (Fohner 2019, Su 2019, Wu 2018, Yampayon 2017, Tassaneeyakul 2016, Chung 2014, Depondt 2011, and Kesavan 2010). For \*1/\*3, this was confirmed by two case reports (McCluggage 2009 and Ninomiya 2000). This is why the KNMP Pharmacogenetics Working Group decided that a gene-drug interaction is present for these genotypes and that dose adjustment is required (yes/yes-interactions).

\*3/\*3: There were 3 cases with this genotype who developed side effects/toxicity on phenytoin (Jose 2008, Ramasamy 2007, and Brandolese 2001). Moreover, studies have found an increased incidence of side effects for \*3/\*3 and \*1/\*3 combined (Su 2019, Wu 2018, Yampayon 2017, Tassaneeyakul 2016 and Chung 2014), for \*3/\*3, \*1/\*3, and \*2/\*3 combined (Kesavan 2010), and for \*3/\*3, \*1/\*3, \*2/\*3, and \*2/\*2 combined (Fohner 2019). \*1/\*3, \*2/\*2, and \*2/\*3 lead to a smaller decrease in enzyme activity than \*3/\*3. This is why the KNMP Pharmacogenetics Working Group decided that this concerns a gene-drug interaction and that dose adjustment is required (yes/yes-interaction).

\*1/\*2: One study with 196 \*1/\*2 showed an increase in the switch to another anticonvulsant in the subset with seizures as indication ( $OR = 1.22$ ), but this increase did not reach statistical significance in the full cohort (Fohner 2019). There was no increase in neurological side effects for \*1/\*2 in this study and other studies did not show an increased incidence of side effects for this genotype either (Kesavan 2010, Azzato 2010, and Hennessy 2009). There was one study that showed an increased incidence of side effects for \*1/\*2 and \*1/\*3 combined (Depondt 2011). Kinetic studies showed similar effects of \*1/\*2 and \*1/\*3 on AUC or plasma concentration (see also below). This is why the KNMP Pharmacogenetics Working Group decided that this concerns a gene-drug interaction and that dose adjustment is required (yes/yes-interaction).

PM: There was 1 case (\*6/\*6) in this genotype group with side effects on phenytoin (Kidd 2001). For this reason and analogous to \*2/\*2, \*2/\*3 and \*3/\*3, the KNMP Pharmacogenetics Working Group decided that this concerns a gene-drug interaction and that dose adjustment is required (yes/yes-interaction).

IM: One study among patients in this genotype group showed a 1.8-fold increase in dose and weight-corrected phenytoin trough concentrations (genotype \*1/IVS8-109T) (Ortega-Vázquez 2016). For this reason and analogous to \*1/\*2 and \*1/\*3, the KNMP Pharmacogenetics Working Group decided that this concerns a

gene-drug interaction and that dose adjustment is required (yes/yes-interaction).

You can find an overview of the clinical and kinetic effects per genotype (group) in the background information text of the gene-drug interactions in the KNMP Kennisbank. You might also have access to this background information text via your pharmacy or physician electronic decision support system.

The justification of the dose recommendations is provided below per genotype/genotype group.

#### *Justification of dose recommendations*

Dose adjustments are calculated on the basis of (dose-corrected) AUC or steady-state plasma concentrations of phenytoin or on the basis of the dose needed to achieve plasma concentrations within the therapeutic range.

- \*1/\*2** Calculations were based on 51 \*1/\*2 derived from 4 studies (Fohner 2019, Ortega-Vazquez 2015, Caraco 2001, and Aynacioglu 1999). The weighted mean of the calculated dose adjustment is a dose reduction to 73% of the normal dose (67%-107%; median 72%). This was translated to a reduction of the dose to 75%, in combination with monitoring of the plasma concentration (TDM).
- \*1/\*3** Calculations were based on 103 \*1/\*3 derived from 8 studies (Fohner 2019, Yamamoto 2016, Hung 2012, Lee 2007, Hung 2004, Caraco 2001, Aynacioglu 1999, and Mamiya 1998). The weighted mean of the calculated dose adjustment is a dose reduction to 66% of the normal dose (51%-140%; median 69%). This was translated to a reduction of the dose to 70%, in combination with monitoring of the plasma concentration (TDM).
- \*2/\*2** Calculations were based on 5 \*2/\*2 derived from 3 studies (Guevara 2017, Caraco 2001, and Aynacioglu 1999). The weighted mean of the calculated dose adjustment is a dose reduction to 56% of the normal dose (37%-63%; median 52%). This was translated to a reduction of the dose to 50%, in combination with monitoring of the plasma concentration (TDM).
- \*2/\*3** There are only data for 1 healthy volunteer with the \*2/\*3 genotype (Caraco 2001). The calculated dose adjustment for this volunteer is a dose reduction to 37% of the normal dose. As a healthy volunteer with the \*2/\*2 genotype in this study had a similar AUC, this was translated to a reduction of the dose to 50%, in combination with monitoring of the plasma concentration (TDM).
- \*3/\*3** Calculations were based on 4 \*3/\*3 derived from 4 studies (Hung 2012, Lee 2007, Kidd 2001, and Aynacioglu 1999). The weighted mean of the calculated dose adjustment is a dose reduction to 40% of the normal dose (22%-70%; median 33%). This was translated to a reduction of the dose to 40%, in combination with monitoring of the plasma concentration (TDM).
- IM** There are no data for IM other (combination of \*1 with a reduced-activity allele other than \*2 or \*3). As the recommendation for IM other is analogous to the recommendation for \*1/\*2 and \*1/\*3 on theoretical grounds, this recommendation is also given here (reduction of the dose to 70-75% of the normal dose, in combination with monitoring of the plasma concentration (TDM)).
- PM** There are no data for PM other (combination of reduced-activity alleles, including at least one allele other than \*2 or \*3). As the recommendation for PM other is analogous to the recommendation for \*2/\*2, \*2/\*3 and \*3/\*3 on theoretical grounds, this recommendation is also given here (reduction of the dose to 40-50% of the normal dose, in combination with monitoring of the plasma concentration (TDM)).

Due to the longer half-life in patients with a gene variant, it will take longer to reach steady-state plasma concentrations. For this reason, the KNMP Pharmacogenetics Working Group recommends to measure plasma concentrations in patients with a gene variant 7-10 days after treatment start or dose adjustment, instead of the normal minimum period of 4-5 days.

#### **Recommendation concerning pre-emptive genotyping, including justification of choices:**

The KNMP Pharmacogenetics Working Group considers genotyping of patients before starting phenytoin maintenance therapy to be essential for drug safety. Genotyping must be performed before maintenance therapy has been initiated to guide dose selection.

The clinical implication of the gene-drug interaction scores 8 out of the maximum of 10 points (with pre-emptive genotyping considered to be essential for scores ranging from 6 to 10 points) (see below and the clinical implication score tables at the end of this risk analysis). The KNMP Pharmacogenetics Working Group restricted the genotyping recommendation to phenytoin maintenance therapy, because genotyping before start of phenytoin for acute indications, like status epilepticus and heart rhythm disorder, is both difficult to implement and not useful because no adjustment of the phenytoin loading dose is recommended in patients with a gene variant.

CYP2C9 gene variants have been shown to increase the risk of severe adverse events, including severe and possibly life-threatening cutaneous adverse events like SJS/TEN and DRESS. In one of the case-control studies showing \*3 to increase SJS/TEN and DRESS risk, the adverse event was fatal in 9 out of the 48 SJS/TEN cases and 4 out of the 42 DRESS cases (code F corresponding to CTCAE grade 5) (Chung 2014). This results in the maximum of 2 points for the first criterion of the clinical implication score, the clinical effect associated with the gene-drug interaction (2 points for code F (CTCAE grade 5)).

Seven studies and three small meta-analyses (of 3, 3 and 4 case-control studies, respectively) showed an increased risk of adverse events with severity D-F (CTCAE grade 3-5). This results in the maximum of 3 points for the second criterion of the clinical implication score, the level of evidence supporting the associated clinical effect grade  $\geq 3$  (3 points for at least three publications with level of evidence score  $\geq 3$ ).



|                                                                                                                                                                                                                                           |                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |              |                                                                                                                                                                              |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                              |                                                                                                                                                                                                                         |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| ref. 1, continuation                                                                                                                                                                                                                      |                                                                                                                                                                                                                         | <table><tr><td>DRESS</td><td>analysis<br/>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis.</td></tr><tr><td>MPE</td><td>NS in univariate analysis and multivariate analysis<br/>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis.</td></tr><tr><td>all cutaneous adverse events</td><td>NS in univariate analysis and multivariate analysis<br/>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis.</td></tr></table> <p>Note: Genotyping was for *3. This is the most important allele in this Thai population.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | DRESS        | analysis<br>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis. | MPE                                                                                                                                                                                                                                     | NS in univariate analysis and multivariate analysis<br>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis. | all cutaneous adverse events | NS in univariate analysis and multivariate analysis<br>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis. |  |
| DRESS                                                                                                                                                                                                                                     | analysis<br>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis.                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |              |                                                                                                                                                                              |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                              |                                                                                                                                                                                                                         |  |
| MPE                                                                                                                                                                                                                                       | NS in univariate analysis and multivariate analysis<br>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis. |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |              |                                                                                                                                                                              |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                              |                                                                                                                                                                                                                         |  |
| all cutaneous adverse events                                                                                                                                                                                                              | NS in univariate analysis and multivariate analysis<br>The percentage of *1/*3 (7.2% in the controls) and of *3/*3 (0% in the controls) also did not differ between cases and tolerant controls in univariate analysis. |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |              |                                                                                                                                                                              |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                              |                                                                                                                                                                                                                         |  |
| ref. 2<br>Fohner AE et al. Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenet Genomics 2019;29:192-9. PMID: 31461080. | 3                                                                                                                                                                                                                       | <p>993 patients were treated with phenytoin (median starting dose 300 mg/day). CYP2C9 genotype was not known during treatment. Data on (dose-adjusted) blood concentrations were available for all patients (of whom 363 with a phenytoin starting dose of 300 mg/day, of whom 331 with reported data), data on switching to an alternative convulsant in 821 patients (of whom 159 with treatment of seizures as indication (as opposed to e.g. neuropathy or seizure prophylaxis following trauma or meningioma resection)), data on adherence and dose reduction in 732 patients (of whom 164 with treatment of seizures as indication), and data on side effects in 382 patients (of whom 232 with treatment of seizures as indication).</p> <p>Neurological side effects were defined as neurological events (i.e., nystagmus, slurred speech, dizziness, somnolence) occurring within 100 days of first phenytoin dispensing.</p> <p>A dose decrease was defined as a decrease in phenytoin dose from first phenytoin daily dose to last phenytoin daily dose within the first year of treatment, adjusted for whether the patient took concomitant anticonvulsants at any point during that year.</p> <p>A switch to an alternative anticonvulsant was defined as filling a prescription for any alternative anticonvulsant in the first 100 days after the first dispensing of phenytoin and not subsequently filling another phenytoin prescription, with no prescription for an alternative anticonvulsant being filled in the 180 days prior to first phenytoin dispensing.</p> <p>Poor patient adherence was defined as a gap of &gt;30 days at any point between the end of supply and the date of a new prescription dispensing record in the first year of treatment.</p> <p>The first therapeutic drug monitoring values were used as blood concentrations.</p> <p>Relevant comedication was not excluded or adjusted for, with the exception of other anticonvulsants.</p> <p>All regression analyses adjusted for age, sex and ethnicity. Regression for neurological side effects and for phenytoin adherence also adjusted for whether the patient was anticonvulsant-naïve. Regression for dose reduction also adjusted for whether the patient was anticonvulsant-naïve and for dual anticonvulsant therapy. Regression for supra-therapeutic first blood concentration also adjusted for starting dose.</p> <p>Genotyping:</p> <table><tr><td>all patients</td><td>phenytoin starting dose of 300 mg/day and concen-</td></tr></table> | all patients | phenytoin starting dose of 300 mg/day and concen-                                                                                                                            | Author's conclusion:<br>"CYP2C9 variation was associated with clinically-meaningful differences in clinician prescribing practice and patient response, with potential implications for healthcare utilization and treatment efficacy." |                                                                                                                                                                                                                         |                              |                                                                                                                                                                                                                         |  |
| all patients                                                                                                                                                                                                                              | phenytoin starting dose of 300 mg/day and concen-                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |              |                                                                                                                                                                              |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                         |                              |                                                                                                                                                                                                                         |  |

ref. 2, continuation

|                                                                                    |                                                                                                   |                                                                                                                                                                                                         |                                                                                                                                                                                                             |                    |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| <div><div>*1/*3+<br/>*2/*2+<br/>*2/*3+<br/>*3/*3: D</div><div>*1/*2: D</div></div> | <div>- 680x *1/*1<br/>- 196x *1/*2<br/>- 85x *1/*3<br/>- 16x *2/*2<br/>- 16x *2/*3 or *3/*3</div> |                                                                                                                                                                                                         | <div>tration data reported<br/>- 231x *1/*1<br/>- 63x *1/*2<br/>- 25x *1/*3<br/>- 12x *2/*2 or *2/*3</div>                                                                                                  |                    |
|                                                                                    | Results:                                                                                          |                                                                                                                                                                                                         |                                                                                                                                                                                                             |                    |
|                                                                                    | Results compared to *1/*1:                                                                        |                                                                                                                                                                                                         |                                                                                                                                                                                                             |                    |
|                                                                                    |                                                                                                   | *1/*3+*2/*2+<br>*2/*3+*3/*3                                                                                                                                                                             | *1/*2                                                                                                                                                                                                       | value for<br>*1/*1 |
|                                                                                    | neurological<br>side effect                                                                       | HR = 2.40<br>(95% CI:<br>1.24-4.64)<br>(S)                                                                                                                                                              | NS                                                                                                                                                                                                          | 17% of<br>patients |
|                                                                                    |                                                                                                   | Trend for an<br>increase in<br>the subset<br>with seizures<br>as indication<br>(p = 0.07).                                                                                                              | Also NS in<br>the subset<br>with seizures<br>as indication.                                                                                                                                                 | 22% of<br>patients |
|                                                                                    | phenytoin<br>dose reduc-<br>tion in the first<br>year                                             | OR = 1.11<br>(95% CI:<br>1.02-1.22)<br>(S).                                                                                                                                                             | NS                                                                                                                                                                                                          |                    |
|                                                                                    |                                                                                                   | After exclu-<br>sion of pa-<br>tients for<br>whom it<br>could not be<br>confirmed<br>that the first<br>phenytoin<br>prescription<br>was indeed<br>the first:<br>trend for an<br>increase (p =<br>0.07). | After exclu-<br>sion of pa-<br>tients for<br>whom it<br>could not be<br>confirmed<br>that the first<br>phenytoin<br>prescription<br>was indeed<br>the first:<br>OR = 2.07<br>(95% CI:<br>1.08-3.95)<br>(S). |                    |
|                                                                                    |                                                                                                   | NS in the<br>subset with<br>seizures as<br>indication.                                                                                                                                                  | Also NS in<br>the subset<br>with seizures<br>as indication.                                                                                                                                                 |                    |
|                                                                                    | switch to<br>another anti-<br>convulsant in<br>the first 100<br>days                              | NS                                                                                                                                                                                                      | Trend for an<br>increase (p =<br>0.08).                                                                                                                                                                     |                    |
|                                                                                    |                                                                                                   | Also NS in<br>the subset<br>with seizures<br>as indication.                                                                                                                                             | OR = 1.22<br>(95% CI:<br>1.05-1.43)<br>(S) in the<br>subset with<br>seizures as<br>indication.                                                                                                              |                    |
|                                                                                    | poor pheny-<br>toin adheren-<br>ce in the first<br>year                                           | OR = 1.95<br>(95% CI:<br>1.12-3.39)<br>(S)                                                                                                                                                              | NS                                                                                                                                                                                                          |                    |
|                                                                                    |                                                                                                   | NS in the<br>subset with<br>seizures as<br>indication.                                                                                                                                                  | Also NS in<br>the subset<br>with seizures<br>as indication.                                                                                                                                                 |                    |
|                                                                                    | first phenytoin                                                                                   | x 1.7 (NS)                                                                                                                                                                                              | x 1.4 (NS)                                                                                                                                                                                                  | 8.8                |

| ref. 2, continuation                                                                                                                                                         |                                                                                                                                                | blood concentration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                   |                                   | µg/ml     | Blood concentration versus *1/*1:<br>*1/*2: 144%<br>*1/*3: 184% |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------|-----------|-----------------------------------------------------------------|-------------------------|----|--------|------------------------------------------------|--------------------------------|-----------|------------|----|------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                              |                                                                                                                                                | supratherapeutic first phenytoin blood concentration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | OR = 7.40 (95% CI: 3.09-17.70) (S)                                | OR = 4.08 (95% CI: 1.79-9.28) (S) |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
|                                                                                                                                                                              |                                                                                                                                                | dose-adjusted first phenytoin blood concentration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | increase with 21.3 pg/ml.mg (S)                                   | increase with 8.6 pg/ml.mg (S)    |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
|                                                                                                                                                                              |                                                                                                                                                | first phenytoin blood concentration on a dose of 300 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | *1/*3: x 1.84 (S)                                                 | x 1.44 (S)                        | 8.8 µg/ml |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
|                                                                                                                                                                              |                                                                                                                                                | Note: Genotyping was for variants mentioned in the Pharm-Var database. Only *2, *3, *5, *8, *11 and *12 were present in this patient group from the USA. Because of the low frequency of the *5, *8, *11 and *12 alleles and the likelihood that not all can be clustered in the same phenotypic category, patients with these alleles were excluded from analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                   |                                   |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
| ref. 3<br>Su SC et al.<br>HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians.<br>Clin Pharmacol Ther<br>2019;105:476-85.<br>PMID: 30270535. | 3                                                                                                                                              | <p>128 Taiwanese cases with phenytoin-induced severe cutaneous adverse events (65 SJS/TEN and 63 DRESS) and 107 patients with phenytoin-induced MPE were compared to 376 phenytoin tolerant controls. Tolerant controls were defined as patients who had taken phenytoin for more than 3 months without evidence for adverse events. In addition, a meta-analysis was performed of these Taiwanese data and data on 129 Thai cases (67 SJS/TEN and 62 DRESS) and 195 tolerant controls and data on 9 Japanese SJS/TEN cases and 94 tolerant controls.</p> <p>The mean daily phenytoin dose was similar among cases and controls.</p> <p>Relevant comedication, like CYP2C9 inhibitors, was not excluded. Patients were included if the ALDEN score for phenytoin causality was ≥4 (SJS/TEN) or the Naranjo score was ≥5 (DRESS).</p> <p>A random effects model was used for the meta-analysis, but prospective registration of the protocol was not mentioned. The selection strategy was not mentioned, but the method of data assessment was transparent.</p> <p>Quality of the included case-control studies was not assessed.</p> <p>Selection bias analysis was not performed.</p> <p>Results:</p> <table><tr><th colspan="4">Cutaneous adverse event risk for (*1/*3+*3/*3) compared to *1/*1:</th></tr><tr><th>cutaneous adverse event</th><th>OR</th><th>95% CI</th><th>*1/*3+*3/*3 frequency in the tolerant controls</th></tr><tr><td rowspan="3">severe cutaneous adverse event</td><td>17.87 (S)</td><td>8.35-38.24</td><td rowspan="3">2%</td></tr><tr><td colspan="2">30% of cases was *3 carrier.</td></tr><tr><td colspan="2">An association was also found in the meta-analysis of the Taiwanese, Thai and Japanese case-control study (OR = 7.12; 95% CI: 2.04-24.82) (S).</td></tr></table> | Cutaneous adverse event risk for (*1/*3+*3/*3) compared to *1/*1: |                                   |           |                                                                 | cutaneous adverse event | OR | 95% CI | *1/*3+*3/*3 frequency in the tolerant controls | severe cutaneous adverse event | 17.87 (S) | 8.35-38.24 | 2% | 30% of cases was *3 carrier. |  | An association was also found in the meta-analysis of the Taiwanese, Thai and Japanese case-control study (OR = 7.12; 95% CI: 2.04-24.82) (S). |  | Author's conclusion:<br>"In addition to cytochrome P450 (CYP) 2C9*3, we found that HLA-B*13:01, HLA-B*15:02, and HLA-B*51:01 were significantly associated with phenytoin hypersensitivity with distinct phenotypic specificities." |
| Cutaneous adverse event risk for (*1/*3+*3/*3) compared to *1/*1:                                                                                                            |                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                   |                                   |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
| cutaneous adverse event                                                                                                                                                      | OR                                                                                                                                             | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | *1/*3+*3/*3 frequency in the tolerant controls                    |                                   |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
| severe cutaneous adverse event                                                                                                                                               | 17.87 (S)                                                                                                                                      | 8.35-38.24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2%                                                                |                                   |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
|                                                                                                                                                                              | 30% of cases was *3 carrier.                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                   |                                   |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |
|                                                                                                                                                                              | An association was also found in the meta-analysis of the Taiwanese, Thai and Japanese case-control study (OR = 7.12; 95% CI: 2.04-24.82) (S). |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                   |                                   |           |                                                                 |                         |    |        |                                                |                                |           |            |    |                              |  |                                                                                                                                                |  |                                                                                                                                                                                                                                     |

|                                                                                                                                                                                                                                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                               |            |                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ref. 3, continuation                                                                                                                                                                                                            |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24% of cases and 4.2% of controls was *3 carrier.<br>Heterogeneity between the case-control studies was significant and high.                                                                                                                                                 |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   | SJS/TEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20.86 (S)                                                                                                                                                                                                                                                                     | 9.03-48.20 |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 34% of cases was *3 carrier.                                                                                                                                                                                                                                                  |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | An association was also found in the meta-analysis of the Taiwanese, Thai and Japanese case-control study (OR = 8.60; 95% CI: 2.85-26.01) (S). 28% of cases and 4.2% of controls was *3 carrier. Heterogeneity between the case-control studies was significant and moderate. |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   | DRESS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16.95 (S)                                                                                                                                                                                                                                                                     | 6.93-41.47 |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27% of cases was *3 carrier.                                                                                                                                                                                                                                                  |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | No association was found in the meta-analysis of the Taiwanese and Thai case-control study (NS). Heterogeneity between the case-control studies was significant and high.                                                                                                     |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   | MPE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 4.20 (S)                                                                                                                                                                                                                                                                      | 1.66-10.63 |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 9% of cases was *3 carrier.                                                                                                                                                                                                                                                   |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   | all                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10.74 (S)                                                                                                                                                                                                                                                                     | 5.16-22.34 |                                                                                                                                                                                                                                                                                                                                                                               |
| 21% of cases was *3 carrier.                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                               |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   | Note 1: In the Taiwanese case-control study, ORs for *3 carriers were higher than for HLA-B*1502 (OR NS for DRESS and MPE and OR 3.01-6.52 for all cutaneous adverse events, severe cutaneous adverse events and SJS/TEN).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                               |            |                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                 |   | Note 2: 72% of the severe cutaneous adverse event cases, 74% of the SJS/TEN cases, 70% of the DRESS cases, and 22% of the controls was carrier of CYP2C9*3, HLA-B*1502, HLA-B*1301, and/or HLA-B*5101. Based on an incidence of severe cutaneous adverse events of 0.45%, the positive predictive value of the presence of one of these 4 alleles for development of a severe cutaneous event was calculated to be 1.4%, the negative predictive value 99.8%, and the number needed to genotype to prevent one severe cutaneous adverse event 310.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                               |            |                                                                                                                                                                                                                                                                                                                                                                               |
| ref. 4<br>Wu X et al.<br>Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.<br>J Clin Pharm Ther 2018;43:408-13.<br>PMID: 29274302. | 4 | Meta-analysis of 4 case-control studies was performed. For tolerant controls, the meta-analysis included 3 studies with a total of 102 SJS/TEN cases and 322 controls. For population controls, the meta-analysis included 3 studies, of which 1 included 3 case-control studies (Chung 2014), with a total of 78 SJS/TEN cases and 4231 controls. All four studies were in Asian patients. With the exception of 2 small case-control substudies in Chung 2014 who could not be scored, all included studies scored 6 of the maximum of 9 points on the Newcastle-Ottawa Scale for study quality. In two of the four studies, all of the patients in the case and control groups received other drugs concomitantly with phenytoin (Yampayon 2017 and Tassaneeyakul 2016), but none were considered to contribute to SJS/TEN in the study populations based on Naranjo and ALDEN algorithms.<br>3 of the 4 studies in this meta-analysis were also included in our risk analysis separately (Yampayon 2017, Tassanee- |                                                                                                                                                                                                                                                                               |            | Authors' conclusion:<br>"A significant association between CYP2C9*3 and phenytoin-induced SJS/TEN was identified, especially in a Thai population. CYP2C9*3 is thus a credible predictive genetic marker of phenytoin-induced SJS/TEN. Further multicentre studies and large prospective observational studies are, however, still required to determine the influence of CYP |

| ref. 4, continuation                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <p>yakul 2016, and Chung 2014).<br/>Meta-analyses were performed with a random-effects model in case of substantial heterogeneity between the studies and a fixed-effects model was chosen otherwise. This indicates that the statistical method was chosen afterwards. The search and selection strategy was transparent and data extraction was standardised.<br/>Publication bias was evaluated with funnel plots (which were not shown).</p> <p>Results:</p> <table><tr><th colspan="4">SJS/TEN risk for (*1/*3+*3/*3) compared to *1/*1:</th></tr><tr><th>controls</th><th>OR</th><th>95% CI</th><th>% *3 carriers in the controls</th></tr><tr><td rowspan="2">tolerant</td><td>8.93 (S)</td><td>2.63-30.36</td><td rowspan="2">4.7%</td></tr><tr><td colspan="2">32% of cases was *3 carrier.</td></tr><tr><td rowspan="2">population</td><td>8.88 (S)</td><td>5.01-15.74</td><td rowspan="2">5.7%</td></tr><tr><td colspan="2">36% of cases was *3 carrier.</td></tr></table> <p>For tolerant controls, heterogeneity between the studies was significant and substantial. Heterogeneity disappeared after exclusion of the Taiwanese study of Chung 2014, leaving only the Thai studies of Yampayon 2017 and Tassaneeyakul 2016.<br/>For population controls, heterogeneity between the studies was not significant.</p> <p>Funnel plots suggested publication bias, but it was difficult to determine publication bias because of the small number of included studies.</p> | SJS/TEN risk for (*1/*3+*3/*3) compared to *1/*1: |  |  |  | controls | OR | 95% CI | % *3 carriers in the controls | tolerant | 8.93 (S) | 2.63-30.36 | 4.7% | 32% of cases was *3 carrier. |  | population | 8.88 (S) | 5.01-15.74 | 5.7% | 36% of cases was *3 carrier. |  | 2C*3 on blood levels of phenytoin and its metabolites, and their association with SJS/TEN." |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|--|--|--|----------|----|--------|-------------------------------|----------|----------|------------|------|------------------------------|--|------------|----------|------------|------|------------------------------|--|---------------------------------------------------------------------------------------------|
| SJS/TEN risk for (*1/*3+*3/*3) compared to *1/*1:                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                   |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |
| controls                                                                                                                                                                                                   | OR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | % *3 carriers in the controls                     |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |
| tolerant                                                                                                                                                                                                   | 8.93 (S)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2.63-30.36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 4.7%                                              |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |
|                                                                                                                                                                                                            | 32% of cases was *3 carrier.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                   |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |
| population                                                                                                                                                                                                 | 8.88 (S)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 5.01-15.74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 5.7%                                              |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |
|                                                                                                                                                                                                            | 36% of cases was *3 carrier.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                   |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |
| ref. 5<br>Guevara N et al. Role of CYP2C9, CYP2C19 and EPHX polymorphism in the pharmacokinetic of phenytoin: a study on Uruguayan Caucasian subjects. Pharmaceuticals (Basel) 2017;10:73. PMID: 28820457. | 3<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>< |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                   |  |  |  |          |    |        |                               |          |          |            |      |                              |  |            |          |            |      |                              |  |                                                                                             |

|                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ref. 6</b><br>Yampayon K et al.<br>Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.<br>Eur J Clin Pharmacol<br>2017;73:855-65.<br>PubMed PMID: 28391407. | 3<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>< |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--|------------------------------------------------|--|---------|------------------------------------|-------|----|---------------|----|--|
| cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 2016;26:225-34. PubMed PMID: 26928377.                                                                                                              | *1/*3+<br>*3/*3: E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <table><tr><td colspan="2">Results:</td></tr><tr><td colspan="2">Effect of *3 on the risk of SJS/TEN and DRESS:</td></tr><tr><td>SJS/TEN</td><td>OR = 4.30 (95% CI: 1.41-13.09) (S)</td></tr><tr><td>DRESS</td><td>NS</td></tr><tr><td>SJS/TEN+DRESS</td><td>NS</td></tr></table> <p>Note: Alleles *2 and *3 were genotyped. *2 was not found in this Thai patient group.</p> | Results: |  | Effect of *3 on the risk of SJS/TEN and DRESS: |  | SJS/TEN | OR = 4.30 (95% CI: 1.41-13.09) (S) | DRESS | NS | SJS/TEN+DRESS | NS |  |
| Results:                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |
| Effect of *3 on the risk of SJS/TEN and DRESS:                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |
| SJS/TEN                                                                                                                                                                                                                      | OR = 4.30 (95% CI: 1.41-13.09) (S)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |
| DRESS                                                                                                                                                                                                                        | NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |
| SJS/TEN+DRESS                                                                                                                                                                                                                | NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |
| ref. 8<br>Ortega-Vázquez A et al. CYP2C9, CYP-2C19, ABCB1 genetic polymor- phisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. Pharmacogeno- mics J 2016;16:286-92. PubMed PMID: 26122019. | 3<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>< |                                                                                                                                                                                                                                                                                                                                                                               |          |  |                                                |  |         |                                    |       |    |               |    |  |

ref. 9, continua-  
tion

| Genotyping                     |                        |
|--------------------------------|------------------------|
| Genotype-guided group (n = 17) | Dosing group (n = 170) |
| - 15x $*1/*1$                  | - 157x $*1/*1$         |
| - 2x $*1/*3$                   | - 13x $*1/*3$          |

| Genotype-based initial dose versus conventional initial dose:          |                                                  |                                     |
|------------------------------------------------------------------------|--------------------------------------------------|-------------------------------------|
|                                                                        |                                                  | Value for conventional initial dose |
| Treatment discontinuation rate due to ineffectiveness or side effects. | Trend (NS; HR <sub>corr</sub> = 0.37; p = 0.074) | 33.1%                               |
| Time to treatment discontinuation                                      | NS                                               | 294 days                            |

|                                     |                                                                                                                                         |                       |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
|                                     |                                                                                                                                         | value<br>for<br>*1/*1 |
| Required<br>phenytoin<br>daily dose | x 0.72 (S)                                                                                                                              | 7.3<br>mg/kg          |
|                                     | The effect was also significant<br>after correction for comedica-<br>tion other than sultiame in<br>multiple regression analysis<br>(S) |                       |
|                                     | Body weight, CYP2C9 and<br>CYP2C19 genotype and sulti-<br>ame use together predicted<br>74% of the variability in dose<br>requirement.  |                       |
| Peak plasma<br>concentration        | x 1.01 (NS)                                                                                                                             | 17.2<br>µg/mL         |

may contribute to avoid intoxication and concentration-dependent adverse effects.”

Dose versus \*1/\*1:  
\*1/\*3: 72%

A case-control study including 168 cases of phenytoin-induced cutaneous side effects (48x SJS/TEN, 42x DRESS and 78x maculopapular exanthema) compared to 130 patients who had used phenytoin for more than 3 months

Authors' conclusion:  
'This study identified  
CYP2C variants,  
including CYP2C9\*3

| <p>phenytoin-related severe cutaneous adverse reactions. JAMA 2014;312:525-34. PubMed PMID: 25096692.</p> <p>ref. 10, continuation</p>                                        | <p>*1/*3+<br/>*3/*3: F</p>                                                       | <p>without developing cutaneous side effects or with the general population (n = 412). Relevant co-medication was not excluded. A total of 13 of the cases died, including 9 SJS/TEN cases and 4 DRESS cases. Doses were determined in 40 cases, plasma concentrations before treatment discontinuation in 9 cases (including 2x *1/*1). Moreover, a meta-analysis was performed for SJS, TEN and DRESS of this and smaller case-control studies in Asian patients, all with the general population as the control group. For SJS/TEN, the meta-analysis included 3 studies involving a total of 61 cases and 3655 controls. For DRESS, the meta-analysis included 2 studies involving a total of 44 cases and 786 controls. ORs in the meta-analysis were calculated using a random-effects model, but prospective registration of the protocol was not mentioned. The selection strategy was not mentioned, but the method of data assessment was transparent. Quality of the included case-control studies was not assessed. Selection bias analysis was not performed.</p> <p>Results:<br/>Case-control study:</p> <table><tr><th colspan="5">(*1/*3 + *3/*3) versus *1/*1:</th></tr><tr><th></th><th colspan="2">Phenytoin control</th><th colspan="2">Population control</th></tr><tr><th></th><th>OR</th><th>95% CI</th><th>OR</th><th>95% CI</th></tr><tr><td>SJS/TEN</td><td>30 (S)</td><td>8.4-109</td><td>14.0 (S)</td><td>6.8-29.0</td></tr><tr><td></td><td colspan="2">42% of the cases had *3.</td><td></td><td></td></tr><tr><td>DRESS</td><td>19 (S)</td><td>5.1-71</td><td>8.8 (S)</td><td>4.0-19.4</td></tr><tr><td></td><td colspan="2">31% of the cases had *3.</td><td></td><td></td></tr><tr><td>Maculopapular exanthema</td><td>5.5 (S)</td><td>1.5-21</td><td>2.6 (S)</td><td>1.1-5.9</td></tr><tr><td colspan="4"></td><td>Value for *1/*1</td></tr><tr><td>Phenytoin peak plasma concentration</td><td colspan="3">x 2.2 (S)<br/>The values for *1/*1 were in line with the values for the controls.</td><td>11 µg/mL</td></tr><tr><td>Daily dose</td><td colspan="3">NS</td><td>304 mg</td></tr></table> <p>Meta-analysis:</p> <table><tr><th colspan="3">(*1/*3 + *3/*3) versus *1/*1:</th></tr><tr><th></th><th>OR</th><th>95% CI</th></tr><tr><td>SJS/TEN</td><td>12.0 (S)</td><td>6.4-22.3</td></tr><tr><td>DRESS</td><td>9.2 (S)</td><td>4.3-19.8</td></tr><tr><td>SJS, TEN or DRESS</td><td>10.6 (S)</td><td>6.2-18.2</td></tr><tr><td colspan="3">There was no study heterogeneity.</td></tr></table> | (*1/*3 + *3/*3) versus *1/*1:    |                 |  |  |  |       | Phenytoin control |                 | Population control                                                                                                                                                                                                                                    |  |  | OR | 95% CI | OR | 95% CI | SJS/TEN | 30 (S) | 8.4-109 | 14.0 (S) | 6.8-29.0 |  | 42% of the cases had *3. |  |  |  | DRESS | 19 (S) | 5.1-71 | 8.8 (S) | 4.0-19.4 |  | 31% of the cases had *3. |  |  |  | Maculopapular exanthema | 5.5 (S) | 1.5-21 | 2.6 (S) | 1.1-5.9 |  |  |  |  | Value for *1/*1 | Phenytoin peak plasma concentration | x 2.2 (S)<br>The values for *1/*1 were in line with the values for the controls. |  |  | 11 µg/mL | Daily dose | NS |  |  | 304 mg | (*1/*3 + *3/*3) versus *1/*1: |  |  |  | OR | 95% CI | SJS/TEN | 12.0 (S) | 6.4-22.3 | DRESS | 9.2 (S) | 4.3-19.8 | SJS, TEN or DRESS | 10.6 (S) | 6.2-18.2 | There was no study heterogeneity. |  |  | <p>known to reduce drug clearance, as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions.'</p> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------|--|--|--|-------|-------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|----|--------|----|--------|---------|--------|---------|----------|----------|--|--------------------------|--|--|--|-------|--------|--------|---------|----------|--|--------------------------|--|--|--|-------------------------|---------|--------|---------|---------|--|--|--|--|-----------------|-------------------------------------|----------------------------------------------------------------------------------|--|--|----------|------------|----|--|--|--------|-------------------------------|--|--|--|----|--------|---------|----------|----------|-------|---------|----------|-------------------|----------|----------|-----------------------------------|--|--|--------------------------------------------------------------------------------------------------------------------------------------------|
| (*1/*3 + *3/*3) versus *1/*1:                                                                                                                                                 |                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               | Phenytoin control                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Population control               |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               | OR                                                                               | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | OR                               | 95% CI          |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| SJS/TEN                                                                                                                                                                       | 30 (S)                                                                           | 8.4-109                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14.0 (S)                         | 6.8-29.0        |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               | 42% of the cases had *3.                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| DRESS                                                                                                                                                                         | 19 (S)                                                                           | 5.1-71                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 8.8 (S)                          | 4.0-19.4        |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               | 31% of the cases had *3.                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| Maculopapular exanthema                                                                                                                                                       | 5.5 (S)                                                                          | 1.5-21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2.6 (S)                          | 1.1-5.9         |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               |                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  | Value for *1/*1 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| Phenytoin peak plasma concentration                                                                                                                                           | x 2.2 (S)<br>The values for *1/*1 were in line with the values for the controls. |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  | 11 µg/mL        |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| Daily dose                                                                                                                                                                    | NS                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  | 304 mg          |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| (*1/*3 + *3/*3) versus *1/*1:                                                                                                                                                 |                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               | OR                                                                               | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| SJS/TEN                                                                                                                                                                       | 12.0 (S)                                                                         | 6.4-22.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| DRESS                                                                                                                                                                         | 9.2 (S)                                                                          | 4.3-19.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| SJS, TEN or DRESS                                                                                                                                                             | 10.6 (S)                                                                         | 6.2-18.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| There was no study heterogeneity.                                                                                                                                             |                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| <p>ref. 11<br/>Hung CC et al. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients. Pharmacogenomics 2012;13:1339-49.</p> | <p>4</p>                                                                         | <p>269 patients received maintenance therapy with phenytoin (mean 315.48 mg/day) as their only anti-epileptic agent. Relevant co-medication was excluded.</p> <p>Genotyping:<br/>- 252x *1/*1<br/>- 16x *1/*3<br/>- 1x *3/*3</p> <table><tr><th colspan="4">*3/*3 versus *1/*3 versus *1/*1:</th></tr><tr><th></th><th>*3/*3</th><th>*1/*3</th><th>Value for *1/*1</th></tr></table>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | *3/*3 versus *1/*3 versus *1/*1: |                 |  |  |  | *3/*3 | *1/*3             | Value for *1/*1 | <p>Authors' conclusion: 'In a multivariate analysis, variants in CYP2C9, CYP2C19, SCN1A, and ABCB1 genes were significantly associated with concentration-dose ratios of phenytoin under adjustment of age, gender and epilepsy classifications.'</p> |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
| *3/*3 versus *1/*3 versus *1/*1:                                                                                                                                              |                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |
|                                                                                                                                                                               | *3/*3                                                                            | *1/*3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Value for *1/*1                  |                 |  |  |  |       |                   |                 |                                                                                                                                                                                                                                                       |  |  |    |        |    |        |         |        |         |          |          |  |                          |  |  |  |       |        |        |         |          |  |                          |  |  |  |                         |         |        |         |         |  |  |  |  |                 |                                     |                                                                                  |  |  |          |            |    |  |  |        |                               |  |  |  |    |        |         |          |          |       |         |          |                   |          |          |                                   |  |  |                                                                                                                                            |

|                                                                                                                                                                                                                                   |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|--------|------------|---------------|----------------------------------------------------------|-----------------------------------------------------------|------------|----------------------------------------------------|-----------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------|------------|------------------------------------------------------------------------|----------------------------------------------------------------------|--|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|------------------------------------------------------------------|
| PubMed PMID: 22966884.<br><br>ref. 11, continuation                                                                                                                                                                               | *1/*3: A<br>*3/*3: AA                                                          | <table><tr><td>Dose-corrected phenytoin plasma concentration</td><td>x 2.32</td><td>x 1.93 (S)</td><td>34.8 day/mL</td></tr><tr><td>Daily dose</td><td>x 0.59</td><td>x 0.68 (S)</td><td>5.65 mg/kg</td></tr><tr><td>Phenytoin plasma concentration</td><td>x 1,06</td><td>x 1,06 (NS)</td><td>15.19 mg/L</td></tr><tr><td colspan="4">Results were similar after Bonferroni correction for multiple testing.</td></tr><tr><td colspan="4">Multivariate regression analysis, which corrected for epilepsy type, weight, age and sex, found an effect on dose-corrected plasma concentration for CYP2C9*3 (S).</td></tr><tr><td colspan="4">Note: genotyping was performed for *3. This is the most important allele in this Han-Chinese population.</td></tr></table>                                                                                                                                                                                                                                                                                                                                                                                              | Dose-corrected phenytoin plasma concentration                              | x 2.32 | x 1.93 (S) | 34.8 day/mL   | Daily dose                                               | x 0.59                                                    | x 0.68 (S) | 5.65 mg/kg                                         | Phenytoin plasma concentration                                                                | x 1,06 | x 1,06 (NS)                                                          | 15.19 mg/L | Results were similar after Bonferroni correction for multiple testing. |                                                                      |  |  | Multivariate regression analysis, which corrected for epilepsy type, weight, age and sex, found an effect on dose-corrected plasma concentration for CYP2C9*3 (S). |              |               |           | Note: genotyping was performed for *3. This is the most important allele in this Han-Chinese population. |                                                                                                                                                                                                                 |  |  | Plasma concentration versus *1/*1:<br>*1/*3: 193%<br>*3/*3: 232% |
| Dose-corrected phenytoin plasma concentration                                                                                                                                                                                     | x 2.32                                                                         | x 1.93 (S)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 34.8 day/mL                                                                |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| Daily dose                                                                                                                                                                                                                        | x 0.59                                                                         | x 0.68 (S)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5.65 mg/kg                                                                 |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| Phenytoin plasma concentration                                                                                                                                                                                                    | x 1,06                                                                         | x 1,06 (NS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15.19 mg/L                                                                 |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| Results were similar after Bonferroni correction for multiple testing.                                                                                                                                                            |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| Multivariate regression analysis, which corrected for epilepsy type, weight, age and sex, found an effect on dose-corrected plasma concentration for CYP2C9*3 (S).                                                                |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| Note: genotyping was performed for *3. This is the most important allele in this Han-Chinese population.                                                                                                                          |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| ref. 12<br>Depondt C et al.<br>A candidate gene study of antiepileptic drug tolerability and -efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011;18:1159-64. PubMed PMID: 21338443. | 3<br><br>*1/*2+<br>*1/*3: D<br>*2/*2: D                                        | <p>137 patients were treated with phenytoin. Relevant co-medication was not excluded. Corrections were made for age, sex and multiple testing.</p> <p>Genotyping:<br/>- 86x *1/*1<br/>- 43x *1/*2<br/>- 6x *1/*3<br/>- 2x *2/*2</p> <p>Results:</p> <table><tr><td colspan="3">% of patients with side effects versus *1/*1 (26%):</td></tr><tr><td>*1/*2 + *1/*3</td><td>x 2.1</td><td rowspan="2">S for the trend *2/*2 versus (*1/*2 + *1/*3) versus *1/*1</td></tr><tr><td>*2/*2</td><td>x 2.0</td></tr></table> <p>Note: Alleles *2 and *3 were genotyped.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | % of patients with side effects versus *1/*1 (26%):                        |        |            | *1/*2 + *1/*3 | x 2.1                                                    | S for the trend *2/*2 versus (*1/*2 + *1/*3) versus *1/*1 | *2/*2      | x 2.0                                              | Authors' conclusion: 'Our results confirm the role of CYP2C9 variants in phenytoin toxicity.' |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| % of patients with side effects versus *1/*1 (26%):                                                                                                                                                                               |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *1/*2 + *1/*3                                                                                                                                                                                                                     | x 2.1                                                                          | S for the trend *2/*2 versus (*1/*2 + *1/*3) versus *1/*1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *2/*2                                                                                                                                                                                                                             | x 2.0                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| ref. 13<br>Kesavan R et al.<br>Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010;66:689-96. PubMed PMID: 20390258.         | 3<br><br>*1/*2: AA<br><br>*1/*3: D<br><br><br><br><br><br><br><br><br>*2/*3: D | <p>292 patients were treated with phenytoin for more than 2 months. Neurotoxicity was defined as occurrence of CNS-related side effects. Phenytoin plasma concentrations were higher in patients with neurotoxicity than in patients without neurotoxicity (23.0 and 9.1 µg/mL respectively) (S). Relevant co-medication was not excluded. ORs were corrected for dose.</p> <p>Genotyping:<br/>- 244x *1/*1<br/>- 14x *1/*2<br/>- 26x *1/*3<br/>- 5x *2/*3<br/>- 3x *3/*3</p> <p>Results:</p> <table><tr><td colspan="3">Risk of neurotoxicity versus *1/*1 (neurotoxicity in 12% of the patients):</td></tr><tr><td>*1/*2</td><td colspan="2">Trend (NS; OR<sub>corr</sub> = 3.5; 95% CI: 0.9 - 12.4)</td></tr><tr><td>*1/*3</td><td colspan="2">OR<sub>corr</sub> = 15.3 (95% CI: 5.8 - 40.3) (S)</td></tr><tr><td>*2/*3</td><td colspan="2">100% of patients had neurotoxicity (NS, significance not determined)</td></tr><tr><td>*3/*3</td><td colspan="2">100% of patients had neurotoxicity (NS, significance not determined)</td></tr><tr><td></td><td></td><td>Value for *1</td></tr><tr><td>*2 (= *1/*2 +</td><td>x 3.1 (S)</td><td>15%</td></tr></table> | Risk of neurotoxicity versus *1/*1 (neurotoxicity in 12% of the patients): |        |            | *1/*2         | Trend (NS; OR <sub>corr</sub> = 3.5; 95% CI: 0.9 - 12.4) |                                                           | *1/*3      | OR <sub>corr</sub> = 15.3 (95% CI: 5.8 - 40.3) (S) |                                                                                               | *2/*3  | 100% of patients had neurotoxicity (NS, significance not determined) |            | *3/*3                                                                  | 100% of patients had neurotoxicity (NS, significance not determined) |  |  |                                                                                                                                                                    | Value for *1 | *2 (= *1/*2 + | x 3.1 (S) | 15%                                                                                                      | Authors' conclusion: "Our results show that CYP2C9 genetic polymorphisms (particularly the *3 allele) were associated with high risk of epileptic patients developing phenytoin-induced neurological toxicity." |  |  |                                                                  |
| Risk of neurotoxicity versus *1/*1 (neurotoxicity in 12% of the patients):                                                                                                                                                        |                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *1/*2                                                                                                                                                                                                                             | Trend (NS; OR <sub>corr</sub> = 3.5; 95% CI: 0.9 - 12.4)                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *1/*3                                                                                                                                                                                                                             | OR <sub>corr</sub> = 15.3 (95% CI: 5.8 - 40.3) (S)                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *2/*3                                                                                                                                                                                                                             | 100% of patients had neurotoxicity (NS, significance not determined)           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *3/*3                                                                                                                                                                                                                             | 100% of patients had neurotoxicity (NS, significance not determined)           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
|                                                                                                                                                                                                                                   |                                                                                | Value for *1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |
| *2 (= *1/*2 +                                                                                                                                                                                                                     | x 3.1 (S)                                                                      | 15%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                            |        |            |               |                                                          |                                                           |            |                                                    |                                                                                               |        |                                                                      |            |                                                                        |                                                                      |  |  |                                                                                                                                                                    |              |               |           |                                                                                                          |                                                                                                                                                                                                                 |  |  |                                                                  |





|                                                                                                                                                                                                                          |                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ref. 21</b><br>Allabi AC et al.<br>CYP2C9, CYP-2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.<br>Pharmacogenet Genomics<br>2005;15:779-86.                         | 3 AA                                             | 109 healthy volunteers, 53x *1/*1, 2x *1/*5, 3x *1/*6, 13x *1/*8, 21x *1/*9, 3x *1/*11, 1x *5/*6, 1x *5/*8, 2x *6/*9, 1x *8/*11, 4x *9/*8, 3x *9/*9, 2x *9/*11, 300 mg single doses of phenytoin, no co-medication;<br><br>No significant differences in phenytoin plasma concentration between CYP2C9 genotypes.<br>Significant association between CYP2C9 genotype and urinary excretion of (S)-p-HPPH.<br>Significant difference in metabolic ratio of phenytoin (ratio (S)-p-HPPH in urine/plasma concentration of phenytoin) between CYP2C9 genotypes.<br><br>Note: Significant association between ABCB1, MDR1 block-2 genotype and plasma concentration.                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                |
| <b>ref. 22</b><br>Janssen P et al.<br>De rol van CYP. Farmacogenetica en kinetiek van fenytoïne [The role of CYP. Pharmacogenetics and kinetics of phenytoin].<br>Pharm Weekblad<br>2005;37:1132-5.                      | 3<br><br><br><br><br>*1/*2+<br>*1/*3: A          | 60 patients, 31x *1/*1 for both 2C9 and 2C19, 18x *1/variant for CYP2C9, ≥ 6-month fixed dose of phenytoin, co-medication known;<br>The CYP2C9 *1/mutation genotype determined V <sub>max</sub> . K <sub>m</sub> was fixed as starting value based on <i>in vitro</i> data.<br>Calculated dose recommendation for a plasma concentration of 14 mg/L based on a kinetic population model: 316 mg/day for CYP2C9 *1/*1, 220 mg/day for CYP2C9*1/mutation.                                                                                                                                                                                                                                                                                                                                                                                                                            | KNMP comment:<br>The same study population as Van der Weide 2001.<br><br>Authors' conclusion:<br>"However, the distribution of the calculated concentrations for a genotype-specific dose is so great, that it remains essential to determine phenytoin concentrations in order to refine the phenytoin dose." |
| <b>ref. 23</b><br>Tate SK et al.<br>Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.<br>Proc Natl Acad Sci USA<br>2005;102:5507-12. | 3<br><br><br>*3/*3: A<br><br>*1/*2,<br>*2/*2: AA | 281 patients, 1x *3/*3, 39x (*1 or 2)/*3, 229x (*1 or *2)/(*1 or *2), phenytoin for ≥ 6 months, unknown co-medication;<br><br>- *3: Significant association between *3 allele and max. required dose. Max. dose was 250 mg for *3/*3, 309 mg for 1x *3 and 354 mg for 0x *3.<br>- *2: No significant association between *2 allele and max. dose.<br><br>Note: genotyping was also performed for ABCB1 and SCN1A (gene that encodes the phenytoin target).<br>Significant association between SCN1A and dose, no association between ABCB1 and dose.                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                |
| <b>ref. 24</b><br>Hung CC et al.<br>Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.<br>Ther Drug Monit<br>2004;26:534-40.                                     | 3<br><br><br>*1/*3: A<br><br><br>*1/*1: A        | 169 patients, 18x CYP2C9*1/*3 (1x CYP2C19 *2/*3, 2x *1/*3, 9x *1/*2, 6x *1/*1), 151x CYP2C9 *1/*1 (6x CYP2C19 *2/*3, 10x *2/*2, 9x *1/*3, 79x *1/*2, 47x *1/*1), phenytoin for ≥ 1 month, other anti-epileptics as co-medication;<br><br>- 2C9*1/*3 + 2C19*1/*1, *1/*2, *1/*3: decrease in dose <sup>a</sup> versus 2C9*1/*1 + 2C19*1/*1 from 5.3 to 4.1 mg/day/kg (S by 23%) and versus 2C9*1/*1 + 2C19*1/*2, *1/*3 from 4.9 to 4.1 (S by 16%). Increased C/D ratio versus 2C9*1/*1 + 2C19*1/*1 from 2.7 to 4.3 (S by 59%) and versus 2C9*1/*1 + 2C19*1/*2, *1/*3 from 3.0 to 4.3 (S by 43%).<br>- 2C9*1/*1 + 2C19*2/*2, *2/*3: decrease in dose <sup>a</sup> versus 2C9*1/*1 + 2C19*1/*1 from 5.3 to 4.3 mg/day/kg (S by 19%) and versus 2C9*1/*1 + 2C19*1/*2, *1/*3 from 4.9 to 4.3 (NS by 12%). Increased C/D ratio versus 2C9*1/*1 + 2C19*1/*1 from 2.7 to 4.0 (S by 48%) and | Authors' conclusion:<br>"The results revealed that the CYP2C9 and CYP2C19 polymorphisms have dramatic effects on the population pharmacokinetic parameters of phenytoin, especially for CYP2C9."<br><br>C <sub>ss</sub> versus *1/*1:<br>*1/*3: 125%.                                                          |



|                                                                                                                                                                                                                                |                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>P450 CYP2C9 on phenytoin dose requirement.</p> <p>Pharmacogenetics 2001;11:287-91.</p> <p>Results were also published in: Pharm Weekblad 2005;16:565-9 and in Ned Tijdschr Geneesk 2001;145:312-5.</p>                      |                                                           | <p>decrease in mean dose from 314 to 199 mg/day (S by 37%).</p> <p>Note: no significant difference in daily dose between the groups with and without co-medication, both for patients with and without mutant alleles. No significant difference in dose between carriers and non-carriers of the CYP2C19*2 allele.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                |
| <p><b>ref. 30</b></p> <p>Kerb R et al.</p> <p>The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.</p> <p>Pharmacogenomics J 2001;1:204-10.</p>                                        | <p>3</p> <p>*2/*2, *3/*3: A</p> <p>*1/*2, *1/*3: A</p>    | <p>96 healthy volunteers, CYP2C9 genotypes: 1x *3/*3, 3x *2/*2, 15x *1/*3, 13x *1/*2, 64x *1/*1, CYP2C19 genotypes: 3x *2/*2, 16x *1/*2, 75x *1/*1, 300 mg single doses of phenytoin, no co-medication;</p> <ul style="list-style-type: none"> <li>- CYP2C9*2/*2+*3/*3: p-HPPH/phenytoin ratio decreased from 1.83 to 0.76 versus *1/*1 (S by 58%). Increased phenytoin concentration versus *1/*1, from 4.20 to 6.41 mg/L (S by 53%).</li> <li>- CYP2C9*1/*2+*1/*3: p-HPPH/phenytoin ratio decreased from 1.83 to 1.34 versus *1/*1 (S by 27%). Increased phenytoin concentration versus *1/*1, from 4.20 to 5.53 mg/L (S by 32%).</li> </ul> <p>Number of mutant CYP2C9 alleles accounts for 14% of the variation in phenytoin plasma concentration.</p> <p>No significant association between CYP2C19*2 allele and concentration of phenytoin or p-HPPH/phenytoin ratio.</p> <p>A total of 35 patients from TDM programme, using phenytoin for &gt; 1 month, co-medication unknown; C/D ratio increases with number of mutant CYP2C9 alleles.</p> | <p>Authors' conclusion: "A combined analysis of variable alleles of CYP2C9, 2C19 and MDR1 revealed that the number of mutant CYP2C9 alleles is a major determinant, the number of MDR 18T alleles further contributes to the prediction of phenytoin plasma levels and CYP2C19*2 does not explain individual variability."</p> |
| <p><b>ref. 31</b></p> <p>Ninomiya H et al.</p> <p>Genetic polymorphism of the CYP-2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.</p> <p>Ther Drug Monit 2000;22:230-2.</p> | <p>2</p> <p>*1/*3: D</p>                                  | <p>Single patient, CYP2C9*1/*3, symptoms of phenytoin intoxication (symptoms of CNS intoxication, ataxia, diplopia) with use of phenytoin 187.5 mg/day, plasma concentration was 32.6 mg/L. No relevant co-medication, CYP-2C19 genotype was *1/*3.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                |
| <p><b>ref. 32</b></p> <p>Aynacioglu AS et al.</p> <p>Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.</p> <p>Br J Clin Pharmacol 1999;48:409-15.</p>               | <p>3</p> <p>*3/*3: AA</p> <p>*1/*3: A</p> <p>*2/*2: A</p> | <p>101 healthy volunteers, 1x *3/*3, 16x *1/*3, 3x *2/*2, 13x *1/*2, 68x *1/*1, 300 mg single doses of phenytoin, no co-medication;</p> <ul style="list-style-type: none"> <li>- *3/*3: increased phenytoin concentration versus *1/*1, from 4.16 to 5.92 mg/L by 42%, decrease in p-HPPH/phenytoin ratio from 0.43 to 0.02 by 95%. Significances unknown.</li> <li>- *1/*3: increased phenytoin concentration versus *1/*1, from 4.16 to 5.65 mg/L (S by 36%), decrease in p-HPPH/phenytoin ratio from 0.43 to 0.21 (S by 51%).</li> <li>- *2/*2: increased phenytoin concentration versus *1/*1, from 4.16 to 6.58 mg/L (S by 58%), decrease in p-HPPH/phenytoin ratio from 0.43 to 0.14 (S by 67%).</li> <li>- *1/*2: increased phenytoin concentration versus *1/*1,</li> </ul>                                                                                                                                                                                                                                                                  | <p>Phenytoin concentration versus *1/*1:</p> <p>*1/*2: 133%</p> <p>*1/*3: 136%</p> <p>*2/*2: 158%</p> <p>*3/*3: 142%</p>                                                                                                                                                                                                       |



|                                                             |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |
|-------------------------------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>ref. 37, continuation</b>                                | <p>*1/*3+<br/>*3/*3: E</p>          | <p>(SCARs) in carriers of the CYP2C9*3 variant with decreased functionality.<br/> <i>CYP2C9 metabolism</i><br/> Phenytoin is metabolised by the CYP450 enzyme CYP2C9. Patients who are carrier of the CYP2C9*2 or CYP2C9*3 variant with decreased functionality (intermediate or poor metabolisers of CYP2C9 substrates) can have a higher risk of increased phenytoin plasma concentrations and resulting toxicity. For patients know to be carrier of the CYP2C9*2 or CYP2C9*3 allele with decreased functionality, careful monitoring of the clinical response is recommended. It might be necessary to monitor the phenytoin plasma concentrations.<br/> <u>Adverse events:</u><br/> Severe cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are reported very rarely. In case of occurrence of these reactions, it is necessary to discontinue phenytoin treatment.<br/> Toxicoderma with eosinophilia and systemic symptoms (DRESS): individual reports indicate that, although they remain very rare, the number of hypersensitivity reactions, like skin rash and liver toxicity, is increased in Blacks.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  |
| <b>ref. 38</b><br>SmPC Dilantin (phenytoin), USA, 03-03-22. | <p>0</p> <p>*1/*3+<br/>*3/*3: E</p> | <p><u>Warning:</u><br/> Serious dermatologic reactions<br/> Dilantin can cause severe cutaneous adverse reactions (SCARs), which may be fatal. Retrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCARs in carriers of the decreased function CYP2C9*3 variant, which has also been associated with decreased clearance of phenytoin. Consider avoiding DILANTIN as an alternative to carbamazepine in CYP2C9*3 carriers.<br/> The use of CYP2C9 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management.<br/> <u>Use in specific populations:</u><br/> Use in patients with decreased CYP2C9 function<br/> Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers. If early signs of dose-related central nervous system (CNS) toxicity develop, serum concentrations should be checked immediately<br/> <u>Clinical pharmacology:</u><br/> <i>Pharmacokinetics</i><br/> Phenytoin is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19. Because phenytoin is hydroxylated in the liver by an enzyme system which is saturable at high serum levels, small incremental doses may increase the half-life and produce very substantial increases in serum levels, when these are in the upper range. The steady-state level may be disproportionately increased, with resultant intoxication, from an increase in dosage of 10% or more.<br/> Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference.<br/> <i>Pharmacogenomics</i><br/> CYP2C9 activity is decreased in individuals with genetic variants such as the CYP2C9*2 and CYP2C9*3 alleles.</p> |  |

|                       |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |
|-----------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| ref. 38, continuation |  | Carriers of variant alleles, resulting in intermediate (e.g., *1/*3, *2/*2) or poor metabolism (e.g., *2/*3, *3/*3) have decreased clearance of phenytoin. Other decreased or nonfunctional CYP2C9 alleles may also result in decreased clearance of phenytoin (e.g., *5, *6, *8, *11).<br>The prevalence of the CYP2C9 poor metabolizer phenotype is approximately 2-3% in the White population, 0.5-4% in the Asian population, and <1% in the African American population. The CYP2C9 intermediate phenotype prevalence is approximately 35% in the White population, 24% in the African American population, and 15-36% in the Asian population. |  |
|-----------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

<sup>a</sup> Corrected for body weight.

<sup>b</sup> Corrected for dose

|            |                                                          |
|------------|----------------------------------------------------------|
| Risk group | *1/*2, *1/*3, *2/*2, *2/*3 and IM with CYP2C9 inhibitors |
|------------|----------------------------------------------------------|

### Comments:

- The only clinical studies included from 2009 are those that included more than 100 patients. Studies investigating cutaneous adverse events were only included if data were (also) provided for severe cutaneous adverse events. Cutaneous adverse events cannot be prevented by dose reduction and the reversibility of mild cutaneous adverse events and low predictive value of CYP2C9 variants for cutaneous adverse events do not warrant avoiding phenytoin in patients with an increased risk. As a result, a therapeutic recommendation is not possible based on data on mild cutaneous adverse events. Kinetic studies were only included if the (dose-corrected) AUC, plasma concentration or clearance was determined per genotype and there were at least three \*1/\*2 or \*1/\*3 or at least one \*2/\*2, \*2/\*3 or \*3/\*3. Other articles do not contribute sufficiently to the burden of proof.
- Taguchi M et al. (Drug Metab Pharmacokinet 2005;20:107-12) found no significant effect of the CYP2C9 genotype on  $V_{max}$  or on  $V_{max}/K_m$ . The study population consisted of 20 patients, both children and adults (2-25 years), 18x \*1/\*1 and 2x \*1/\*3.
- Existing guidelines:  
Caudle KE et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014;96:542-8. PubMed PMID: 25099164 and Karnes JH et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther 2021;109:302-9. PMID: 32779747. CPIC indicates that *in vitro* and clinical studies suggest that CYP2C9 decreased function and no or almost no function alleles generate variant enzymes with activities that are substrate-dependent. Therefore, assigning function to CYP2C9 alleles requires careful evaluation of individual drugs. Despite this, CPIC does not distinguish between the \*1/\*3 and \*2/\*2 genotypes and between the \*2/\*3 and \*3/\*3 genotypes. CPIC assigns an activity score of 1 to fully functional CYP2C9 alleles, an activity score of 0.5 to CYP2C9 alleles with reduced but not (almost) no function like \*2, and an activity score of 0 to CYP2C9 alleles with (almost) no function like \*3. CPIC groups genotypes into phenotypes based on activity score and sometimes distinguishes different activity scores within a phenotype. The CPIC phenotype normal metaboliser (NM) only contains gene activity score 2 (\*1/\*1). The CPIC phenotype intermediate metaboliser (IM) contains gene activity scores 1 (including both \*1/\*3 and \*2/\*2) and 1.5 (including \*1/\*2), so CPIC never distinguishes between \*1/\*3 and \*2/\*2. CPIC indicates that allocation of \*1/\*3 and \*2/\*2 into one group is based on data for multiple substrates (flurbiprofen, celecoxib, phenytoin, and warfarin) showing a similar effect of \*1/\*3 and \*2/\*2 on metabolic ratio and dose requirements (warfarin) (Vogl S et al. CYP2C9 genotype vs. metabolic phenotype for individual drug dosing - a correlation analysis using flurbiprofen as probe drug. PLoS One 2015;10:e0120403; Kusama M et al. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm Res 2009;26: 822-35 PubMed: 19082874; and Lindh JD et al. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol 2009;65:365-75. PubMed: 19031075). The CPIC phenotype poor metaboliser (PM) contains gene activity scores 0 (including \*3/\*3) and 0.5 (including \*2/\*3). So, CPIC can distinguish between \*2/\*3 and \*3/\*3, but does not do so for phenytoin. The summary below follows the KNMP definitions for IM (i.e. IM OTHER) and PM (i.e. PM OTHER).  
CPIC indicates that there is substantial evidence linking CYP2C9 genotypes with phenotypic variability. CPIC states that the available literature provides consistent, high quality evidence for the relationship between genetic variation and phenotypic variability. CPIC originally mentioned that available estimates from models indicate that CYP2C9 variant alleles lead to lower phenytoin clearance, depending on the allele and the number of alleles. Several studies have shown that \*1/\*2 and \*1/\*3 lead to moderate decreases in clearance. Phenytoin maintenance doses were decreased by 23-38% versus \*1/\*1 in these genotypes (Hung 2004, Van der Weide 2001, Hung 2012). In the update, references were only included in the supplementary files. CPIC indicates that availa-

ble evidence does not clearly indicate the extent of dose reduction needed to prevent phenytoin-related toxicities in \*1/\*3, \*2/\*2, IM OTHER with an (almost) no function allele, and PM OTHER without an (almost) no function allele. CPIC indicates that multiple case studies have observed an increased risk for exposure-related phenytoin toxicities (originally mentioned references: Brandolese 2001, Ramasamy 2007, Hennessy 2009 and Dorado 2013; last reference not included in our risk analysis), and that multiple studies have observed an association between the \*3 allele and SJS/TEN (Yampayon 2017, Tassaneeyakul 2016, and Chung 2014). Although carriage of the CYP2C9\*3 allele is insufficient to predict phenytoin-induced SJS/TEN, these and other data suggest that the risk of SJS/TEN is dose-related and provide an additional rationale for reducing phenytoin dose in patients with two reduced function alleles of which at least one an (almost) no function allele (Karnes JH et al. Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions. *Annu Rev Pharmacol Toxicol* 2019;59:463-86. PubMed: 30134124). CPIC indicates that available evidence does not clearly indicate the extent of dose reduction needed to prevent phenytoin-related toxicities in these patients.

CPIC indicates that (fos)phenytoin dose should first be adjusted according to a patient's clinical characteristics. In patients with \*1/\*2 or in IM OTHER with the reduced function allele not being an (almost) no function allele, CPIC indicates that the recommended phenytoin initial or loading and maintenance doses do not need adjustments based on genotype. CPIC classifies this recommendation as moderate, meaning that there is a close or uncertain balance as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects. CPIC indicates that their dose recommendations are conservative given the variability surrounding phenytoin dosing. Based on the doses reported in the pharmacokinetic and pharmacogenetic studies (Hung 2012, Hung 2004, Van der Weide 2001, and other studies mentioned only in the supplementary files), CPIC states that a typical initial or loading dose followed by at least a 25% reduction in the recommended starting maintenance dose may be considered for \*1/\*3, \*2/\*2, IM OTHER with an (almost) no function allele, and PM OTHER without an (almost) no function allele. Subsequent maintenance doses should be adjusted based on therapeutic drug monitoring and response. CPIC classifies this recommendation as moderate, meaning that there is a close or uncertain balance as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects. For \*2/\*3, \*3/\*3 and PM OTHER with at least one (almost) no function allele, CPIC recommends to use a typical initial or loading dose then to consider at least a 50% reduction of starting maintenance dose with subsequent maintenance doses adjusted based on therapeutic drug monitoring and response. CPIC classifies this recommendation as strong, meaning that the evidence is high quality and the desirable effects clearly outweigh the undesirable effects.

CPIC indicates that, while limited data are available for effects of CYP2C9 alleles on phenytoin metabolism in paediatric patient populations, there is no compelling data to indicate that CYP2C9 polymorphisms will affect phenytoin metabolism differently in children compared to adults. As such, the paediatric recommendation was extrapolated using adult data.

CPIC indicates that some studies suggest that variants in other genes also contribute to altered phenytoin metabolism (e.g., CYP2C19, CYP1A1, and EPHX1 (reviewed in Thorn CF et al. PharmGKB summary: phenytoin pathway. *Pharmacogenet Genomics* 2012;22:466-70. PubMed: 22569204)) and combined genetic analysis might improve the prediction of phenytoin metabolism (Hung 2012 and Hung 2004). However, these studies evaluating the effect of multiple gene variation and phenytoin dose requirements are limited and have not been replicated. Consequently, the CPIC guideline on genotype-directed phenytoin dosing is limited to CYP2C9. CPIC indicates that if both HLA-B\*1502 and CYP2C9 genotypes are known, the HLA-B\*1502 genotype should be considered first, then CYP2C9 genotype.

The recommendations for patients with variant CYP2C9 genotypes are as follows:

| CYP2C9 genotype                                                                                                     | Therapeutic recommendation                                                                                                                                                                                                                                                                                                                                                                                     | Classification of recommendation |
|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| *1/*2 and IM OTHER with the reduced function allele not being an (almost) no function allele                        | No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*1502 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice.<br>(i.e. the same recommendation as given for *1/*1.)                          | Moderate <sup>a</sup>            |
| *1/*3, *2/*2, and IM OTHER with an (almost) no function allele, and PM OTHER without an (almost) no function allele | For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*1502 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice. | Moderate <sup>a</sup>            |

|                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                |                     |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| *2/*3, *3/*3, and PM OTHER with at least one (almost) no function allele | For first dose, use typical initial or loading dose. For subsequent doses, use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*1502 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice. | Strong <sup>b</sup> |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|

<sup>a</sup>: There is a close or uncertain balance as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects.

<sup>b</sup>: The evidence is high quality and the desirable effects clearly outweigh the undesirable effects.

On 3-5-2022, there was not a more recent version of the recommendations present on the CPIC-site.

Date of literature search: 23 April 2022.

|                                              | Genotype | Code | Gene-drug interaction | Action | Date        |
|----------------------------------------------|----------|------|-----------------------|--------|-------------|
| KNMP Pharmacogenetics Working Group decision | *1/*2    | 4 D  | yes                   | yes    | 23 May 2022 |
|                                              | *1/*3    | 4 F  | yes                   | yes    |             |
|                                              | *2/*2    | 4 D  | yes                   | yes    |             |
|                                              | *2/*3    | 4 D  | yes                   | yes    |             |
|                                              | *3/*3    | 4 F  | yes                   | yes    |             |
|                                              | IM       | -    | yes                   | yes    |             |
|                                              | PM       | 2 D  | yes                   | yes    |             |

#### Mechanism:

Phenytoin is predominantly metabolised by CYP2C9 (90%) and also by CYP2C19 (10%), to the inactive metabolite para-hydroxyphenytoin (5-(para-hydroxyphenyl)-5-phenylhydantoin, p-HPPH). Formation of this metabolite goes through an unstable arene-oxide intermediate.

Unlike most side effects are the immune-mediated cutaneous adverse events usually (largely) concentration independent. Analogy with other drug-induced cutaneous adverse events suggests the following mechanism. A cellular immune reaction against tissue cells is induced if peptides derived from proteins within these tissue cells bind to specific HLA proteins, are transported to the cell surface and are "recognised" as foreign by specific immune cell proteins (T-cell receptors). (A metabolite of) phenytoin binds to either the cellular proteins or derived peptides, to specific HLA proteins or to specific T-cell receptors, thus inducing an interaction between an HLA peptide complex and a T-cell receptor, resulting in a cellular immune reaction against tissue cells. Thus, the effect of CYP2C9 variants on the risk of severe cutaneous adverse events is most likely not mediated by the increased phenytoin concentrations, but by a change in metabolites formed or a disbalance in the rates of formation and detoxification of the unstable arene-oxide intermediate.

Phenytoin exhibits non-linear pharmacokinetics. With chronic use, phenytoin induces CYP450 enzymes, primarily CYP2C9 and CYP2C19. So, phenytoin induces its own metabolism. However, because CYP2C9 and CYP2C19 are saturable at high phenytoin serum concentrations, small incremental doses may produce very substantial increases in serum concentrations, when these are in the upper range.

The NVZA mentions the following therapeutic ranges: 8-20 µg/ml (total phenytoin) and 0.5-2 µg/ml (free phenytoin). The NVZA mentions the following toxic concentrations: > 20 µg/ml (total phenytoin) and > 2 µg/ml (free phenytoin). The NVZA indicates that plasma concentrations should be measured after at least 4-5 days.

#### Clinical Implication Score:

Table 1: Definitions of the available Clinical Implication Scores

|                               |                                                                                                                                                                                                                              |        |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| <b>Potentially beneficial</b> | PGx testing for this gene-drug pair is potentially beneficial. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the DPWG recommends adhering to the gene-drug guideline. | 0-2 +  |
| <b>Beneficial</b>             | PGx testing for this gene-drug pair is beneficial. It is advised to consider genotyping the patient before (or directly after) drug therapy has been initiated to guide drug and dose selection.                             | 3-5 +  |
| <b>Essential</b>              | PGx testing for this gene-drug pair is essential for drug safety or efficacy. Genotyping must be performed before drug therapy has been initiated to guide drug and dose selection.                                          | 6-10 + |

Table 2: Criteria on which the attribution of Clinical Implication Score is based

| <b>Clinical Implication Score Criteria</b>                                                                                                                                                                                                                                                                                                                                                             | <b>Possible Score</b> | <b>Given Score</b> |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------|
| <b>Clinical effect associated with gene-drug interaction (drug- or diminished efficacy-induced)</b> <ul style="list-style-type: none"> <li>CTCAE Grade 3 or 4 (clinical effect score D or E)</li> <li>CTCAE Grade 5 (clinical effect score F)</li> </ul>                                                                                                                                               | +<br>++               | ++                 |
| <b>Level of evidence supporting the associated clinical effect grade <math>\geq 3</math></b> <ul style="list-style-type: none"> <li>One study with level of evidence score <math>\geq 3</math></li> <li>Two studies with level of evidence score <math>\geq 3</math></li> <li>Three or more studies with level of evidence score <math>\geq 3</math></li> </ul>                                        | +<br>++<br>+++        | +++                |
| <b>Number needed to genotype (NNG) in the Dutch population to prevent one clinical effect grade <math>\geq 3</math></b> <ul style="list-style-type: none"> <li><math>100 &lt; \text{NNG} \leq 1000</math></li> <li><math>10 &lt; \text{NNG} \leq 100</math></li> <li><math>\text{NNG} \leq 10</math></li> </ul>                                                                                        | +<br>++<br>+++        | ++<br><br>+        |
| <b>PGx information in the Summary of Product Characteristics (SmPC)</b> <ul style="list-style-type: none"> <li>At least one genotype/phenotype mentioned</li> </ul> OR <ul style="list-style-type: none"> <li>Recommendation to genotype</li> </ul> OR <ul style="list-style-type: none"> <li>At least one genotype/phenotype mentioned as a contra-indication in the corresponding section</li> </ul> | +<br><br>++<br><br>++ | +                  |
| <b>Total Score:</b>                                                                                                                                                                                                                                                                                                                                                                                    | 10+                   | 8+                 |
| <b>Corresponding Clinical Implication Score:</b>                                                                                                                                                                                                                                                                                                                                                       |                       | Essential          |